Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, announces positive Interim Results in Phase I/II HuMax®-CD20 CLL Study15 Sept 2005
Genmab, articles of association31 Aug 2005
Genmab, Capital Increase as a Result of Employee Warrant Exercise30 Aug 2005
Genmab, articles of association as per August 18, 200524 Aug 2005
Genmab, to Present Interim Results in Phase I/II HuMax®-CD20 CLL Study22 Aug 2005
Genmab, Serono and Genmab Announce Global Development and Commercialization Agreement for HuMax-CD418 Aug 2005
Genmab, Announcement of Additional Details Concerning Direct Placement of Genmab Shares to Serono18 Aug 2005
Genmab, notification from major shareholder (section 29) from Ares Trading S.A.
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
18 Aug 2005
Genmab, nitiates HuMax®-CD20 Phase II Study in Rheumatoid Arthritis16 Aug 2005
Genmab, Grant of Warrants10 Aug 2005
Genmab, interim report - six months9 Aug 2005
Genmab, Announces 2005 First Half Year Results9 Aug 2005
  • Previous
  • 1
  • More pages
  • 132
  • 133
  • 134
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863